All In Biotech

Drug Trial Radar · NCT03761225

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Docetaxel to Placebo in Combination With Docetaxel in First Line Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 714 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

714

Actual

Start

Sep 2014

Primary completion

Dec 15, 2020

Study completion Dec 15, 2020

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Dec 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer

Interventions

  • MasitinibDrug

  • DocetaxelDrug

  • PrednisoneDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, Canada

  • Polyclinique d'oncologie de Gentilly

    Nancy, France

  • Sanjay Gandhi Post Graduate Institute of Medical Sciences

    Lucknow, India

  • Centro di Riferimento Oncologico

    Aviano, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

  • Universiti Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Clinical Oncology Dispensary

    Omsk, Russia

  • Clinic Andros LLC

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.